Healthcare

https://techpapersworld.com/wp-content/uploads/2024/11/EDAN-Unveils-Latest-Innovations-1280x720.jpg

HealthcareEDAN Unveils Latest Innovations for Global Healthcare at MEDICA 2024

Edan Instruments Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, showcased its latest product innovations at MEDICA 2024 in Germany. The event, held from November 11 to 14, attracted over 83,000 attendees and 5,300 exhibitors, highlighting advancements in healthcare technology. “Approaching its 30th anniversary, EDAN’s presence this year underscores our commitment to practical, adaptable healthcare solutions for real-world challenges,” said Brian He, Senior regional sales director of EDAN. “Our latest innovations are shaped by constant feedback...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/While-More-Is-Better-Even-1280x720.jpg

HealthcareWhile More Is Better, Even Moderate Amounts of Exercise May Reduce Risk for Common Heart Condition

Adding an extra hour every week of physical activity may lower the chance of developing the most common type of irregular heartbeat (arrythmia) by 11%, a new study shows. Led by researchers at NYU Langone Health, the investigation focused on atrial fibrillation, a condition in which the heart’s upper two chambers beat rapidly and irregularly instead of at a consistent pace. If left untreated, this can lead to stroke, heart failure, and other issues. While...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2023/11/AI-Identifies-Non-smokers-1280x720.jpg

HealthcareDizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of sunvozertinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Groupe-Mutuel-integrates-Ada-Health-1-1280x720.jpg

HealthcareGroupe Mutuel integrates Ada Health’s AI-powered care navigation into their member experience across Switzerland to support personalized, streamlined access to care

Ada Health, the leading global AI health assessment and care navigation platform, and Groupe Mutuel, the comprehensive insurer, have launched a partnership to support quicker and easier access to affordable, effective care for up to 1.4 million Groupe Mutuel members across Switzerland. Through this partnership, Ada’s clinically validated AI helps Groupe Mutuel offer tailored healthcare experiences for their members. For these members, Ada’s on-demand, trustworthy health assessments support them by navigating them to a wide array of...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Oxford-Nanopore-Announces-Landmark-UK-Government-1280x720.jpg

HealthcareOxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK

Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore, to support the government’s vision to build an NHS “fit for the future” by enabling genomics-based translational research and accelerating the development and adoption of Oxford Nanopore’s ground-breaking genomics technology in the NHS....

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/First-Rounds-of-Late-Breaking-1280x720.jpg

HealthcareFirst Rounds of Late-Breaking Clinical Trial Results Announced at VIVA24

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds of Late-Breaking Clinical Trials presented at the VIVA24 conference, at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of lectures and live case presentations from clinical centers around the world. The...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Brown-Books-Kids-Publishes-Young-Hockey-Player-1280x720.jpg

HealthcareBrown Books Kids Publishes Young Hockey Player’s Heartfelt Leukemia Survival Story Timed to Hockey Fights Cancer Month

Former Houghton Mifflin Harcourt executive David P. Kavanaugh releases debut children’s book, Dinky Donkey Doo: A Brave Boy, His Loyal Protector, and a Journey of Hope, based on the true story his son Jack — a hockey player, animal lover and leukemia survivor. This captivating story gives young readers a delicate glimpse into a young boy’s cancer journey — bringing about an inspirational message of how kindness and friendship teaches us to stay strong. While undergoing treatment,...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/10/TME-Pharma-Awarded-E2.4-Million-German-1280x720.jpg

HealthcareTME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that it is awarded a non-refundable grant of €2.4 million from the KMU-innovativ funding program run by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF). The non-dilutive non-refundable funding will support TME Pharma’s planned Phase 2 randomized controlled study evaluating its lead asset, the CXCL12 inhibitor NOX-A12,...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Cancer-trial-retraining-immune-1280x720.jpg

HealthcareCancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the script: we isolate immune cells from this suppressive environment, we reactivate their inherent cancer-fighting abilities in a laboratory, and return them back to the patient”, said Dr Frank Borriello, Founder and CEO of Boston-based Alloplex...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Largest-university-hospital.jpg

HealthcareLargest university hospital in Belgium chooses digital pathology from Sectra to further enhance cancer diagnostics

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an enterprise imaging contract with Belgium’s largest university hospital, UZ Leuven. The healthcare provider will utilize the module for digital pathology, providing pathologists with a digital solution designed for full-scale primary diagnostics. This will save valuable time for both clinicians and patients, further enhancing cancer care. “We have been using digital pathology in a limited capacity for multiple years. As we now take the step to go...

Newer Posts

Older Posts